LONDON - Incanthera plc, a specialist in dermatology and oncology innovations, has reported significant advancements in the six months leading up to September 30, 2024. The company announced its interim results, highlighting the preparations for the launch of its luxury skincare line, Skin + CELL.
In the first half of the year, Incanthera raised £3.4 million through equity fundraising and warrant exercises. The funds were primarily allocated to stockpiling inventory for the Skin + CELL range, produced in collaboration with the Frike Group, a contract manufacturer based in Zurich.
Despite this progress, Incanthera faced a challenge post-reporting period when, on November 26, 2024, the company was confronted with unsubstantiated third-party allegations of potential patent infringement related to the Skin + CELL product formulations. Incanthera considers these allegations to be baseless and is determined to resolve the issue.
The Board expressed its continued confidence in the successful future launch of the skincare products and committed to keeping the market informed.
This news is based on a press release statement from Incanthera plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.